About us Contacts Drug interactions: 390 212
Drug search by name

Acunivive 90 Injection System and Pralatrexate Intravenous

Determining the interaction of Acunivive 90 Injection System and Pralatrexate Intravenous and the possibility of their joint administration.

Check result:
Acunivive 90 Injection System <> Pralatrexate Intravenous
Relevance: 11.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ketorolac may increase the blood levels and side effects of PRALAtrexate. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor immediately if you develop symptoms of potentially serious side effects of PRALAtrexate such as mouth ulcers or sores; vomiting; diarrhea; rash; loss of appetite; joint pain or swelling; yellow discoloration of skin and eyes; dark urine; paleness; dizziness or fainting; unusual bruising or bleeding; infection; and flu-like symptoms (fever, chills, body aches, sore throat, muscle weakness). It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with drugs that are subject to substantial renal clearance such as trimethoprim/sulfamethoxazole and nonsteroidal anti-inflammatory drugs (NSAIDs) may result in delayed clearance of pralatrexate. The mechanism is competitive inhibition of renal excretion, as approximately 34% of pralatrexate is eliminated unchanged by the kidney.

MANAGEMENT: Caution is advised if pralatrexate is prescribed in combination with trimethoprim/sulfamethoxazole or NSAIDs. Complete blood cell counts as well as renal and hepatic function should be closely monitored. Treatment interruption or dose reduction of pralatrexate may be required if toxicities such as mucositis, myelosuppression, or liver enzyme abnormalities develop. Patients should be advised to contact their physician if they develop oral ulcers, painful swallowing, vomiting, diarrhea, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.

References
  • "Product Information. Folotyn (pralatrexate)." Allos Therapeutics, Westminster, CO.
Acunivive 90 Injection System

Generic Name: ketorolac

Brand name: Sprix, Toradol

Synonyms: Ketorolac (nasal), Ketorolac (Nasal)

Pralatrexate Intravenous

Generic Name: pralatrexate

Brand name: Folotyn

Synonyms: Pralatrexate (Intravenous), PRALAtrexate, Pralatrexate

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.